Milestone marks the first clinical program for Charcot-Marie-Tooth disease and Vanishing White Matter disease.
Expanded collaboration continues to leverage Congruence's proprietary computational drug discovery engine, Revenir™ to deliver Development Candidates in ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results